Aimaz Afrough
About
Aimaz Afrough is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Aimaz Afrough has authored 33 papers receiving a total of 205 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 14 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Aimaz Afrough's work include Multiple Myeloma Research and Treatments (18 papers), CAR-T cell therapy research (8 papers) and Protein Degradation and Inhibitors (5 papers). Aimaz Afrough is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), CAR-T cell therapy research (8 papers) and Protein Degradation and Inhibitors (5 papers). Aimaz Afrough collaborates with scholars based in United States, Azerbaijan and India. Aimaz Afrough's co-authors include Richard E. Champlin, Amir Hamdi, Gabriela Rondón, Zahra Mahmoudjafari, Partow Kebriaei, Gurbakhash Kaur, Hamza Hashmi, Muzaffar H. Qazilbash, Al‐Ola Abdallah and Uday Popat and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Aimaz Afrough
25 papers receiving 204 citations
Peers
Aimaz Afrough
Shin‐ichi Fuchida Japan
Cristina Castilla‐Llorente France
Yongsheng Ruan China
Natalie Schub Germany
Warda Faridi United States
Chongsheng Qian China
Rikako Tabata Japan
Maximilian Fleischmann Germany
Sanbin Wang China
Anne Lok France
Citations per year, relative to Aimaz Afrough Aimaz Afrough (= 1×)
peers
Shin‐ichi Fuchida
Countries citing papers authored by Aimaz Afrough
Since
Specialization
Citations
This map shows the geographic impact of Aimaz Afrough's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aimaz Afrough with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aimaz Afrough more than expected).
Fields of papers citing papers by Aimaz Afrough
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Aimaz Afrough. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aimaz Afrough. The network helps show where Aimaz Afrough may publish in the future.
Co-authorship network of co-authors of Aimaz Afrough
This figure shows the co-authorship network connecting the top 25 collaborators of Aimaz Afrough. A scholar is included among the top collaborators of Aimaz Afrough based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aimaz Afrough. Aimaz Afrough is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Banerjee, Rahul, Mengru Wang, Xiaoliang Wang, et al.. (2025). Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis. Blood Cancer Journal. 15(1). 48–48.
2.
Afrough, Aimaz, Nina Kim, Jinghua He, et al.. (2024). Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings. Blood. 144(Supplement 1). 933–933.
3.
Afrough, Aimaz, et al.. (2024). Toxicity of CAR T-Cell Therapy for Multiple Myeloma. Acta Haematologica. 148(3). 1–15.
4.
Atrash, Shebli, Aimaz Afrough, Barry Skikne, et al.. (2024). Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy. Transplantation and Cellular Therapy. 30(2). S373–S373.
5.
Kroger, Benjamin, Umar Khan, Robert H. Collins, et al.. (2023). Abstract 5925: Prevalence of clonal hematopoiesis in patients with monoclonal gammopathy of undetermined significance. Cancer Research. 83(7_Supplement). 5925–5925.
6.
Mansour, Razan, Hamza Hashmi, Aimaz Afrough, et al.. (2023). Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics. Blood. 142(Supplement 1). 1985–1985.
7.
Afrough, Aimaz, Hamza Hashmi, Doris K. Hansen, et al.. (2023). P-002 Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: real-world experience from the U.S. myeloma CAR T consortium. Clinical Lymphoma Myeloma & Leukemia. 23. S33–S33.
8.
Dima, Danai, James A. Davis, Nausheen Ahmed, et al.. (2023). Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience. Transplantation and Cellular Therapy. 30(3). 308.e1–308.e13.
9.
Anderson, John, Aimaz Afrough, Larry D. Anderson, et al.. (2023). Impact of the Affordable Care Act and Medicaid Expansion on Insurance Coverage and Outcomes in Patients with HIV‐associated Aggressive B‐cell Non‐Hodgkin Lymphomas. Hematological Oncology. 41(S2). 243–244.
10.
Atrash, Shebli, Aimaz Afrough, Zahra Mahmoudjafari, et al.. (2023). Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT).. Journal of Clinical Oncology. 41(16_suppl). e20044–e20044.
11.
Afrough, Aimaz, Hamza Hashmi, Doris K. Hansen, et al.. (2023). Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.. Journal of Clinical Oncology. 41(16_suppl). 8013–8013.
12.
Gutierrez‐Barrera, Angelica M., et al.. (2022). Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in BRCA1/2: Overall Survival, Racial, and Ethnic Differences. The Breast Journal. 2022. 1–9.
13.
Ghobadi, Armin, Denái R. Milton, Lohith Gowda, et al.. (2019). HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Current Research in Translational Medicine. 67(2). 51–55.
14.
Afrough, Aimaz, Rima M. Saliba, Amir Hamdi, et al.. (2018). Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 24(11). 2197–2203.
15.
Varma, Ankur, Rima M. Saliba, Maximilian Stich, et al.. (2017). Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation. 23(4). 581–587.
16.
Varma, Ankur, Rima M. Saliba, Harrys A. Torres, et al.. (2016). Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplantation. 51(7). 999–1001.
17.
Afrough, Aimaz, Rima M. Saliba, Amir Hamdi, et al.. (2015). Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 21(8). 1413–1417.
18.
Hamdi, Amir, Aimaz Afrough, Tariq Muzzafar, et al.. (2014). Donor Cell–Derived Myelodysplastic Syndrome With Ring Chromosome 7 After Allogeneic Hematopoietic Stem Cell Transplant in 2 Patients With Lymphomas as Primary Disease. Clinical Lymphoma Myeloma & Leukemia. 14(5). e151–e155.
19.
Kuerer, Henry M., Heather Lin, Angelica M. Gutierrez‐Barrera, et al.. (2014). Predictors that Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing. Annals of Surgical Oncology. 21(11). 3466–3472.
20.
Hamdi, Amir, Raya Mawad, Roland L. Bassett, et al.. (2014). Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 20(11). 1767–1771.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Shin‐ichi Fuchida Breakdown of academic impact, for papers by Cristina Castilla‐Llorente Breakdown of academic impact, for papers by Yongsheng Ruan Breakdown of academic impact, for papers by Natalie Schub Breakdown of academic impact, for papers by Warda Faridi Breakdown of academic impact, for papers by Chongsheng Qian Breakdown of academic impact, for papers by Rikako Tabata Breakdown of academic impact, for papers by Maximilian Fleischmann Breakdown of academic impact, for papers by Sanbin Wang Breakdown of academic impact, for papers by Anne Lok